Real-world study reveals optimal strategies for breast cancer patients resistant to leading drugs
NCT ID NCT07587983
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 220 women with HER2-low advanced breast cancer whose disease progressed after antibody-drug conjugate (ADC) therapy. Researchers compared different follow-up treatments, such as other ADCs, chemotherapy, hormone therapy, or immunotherapy, to see which worked best. The goal is to help doctors choose the most effective next step for these patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, 210029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?